Now, Novo Nordisk’s push to limit compounding could leave many patients in a tough spot. If the FDA adds semaglutide to the DDC list, compounding pharmacies would no longer be able to offer their version, regardless of supply constraints. And this comes on the heels of another significant d...
From a legal and FDA standpoint, the implications are unclear. However, it's safer to assert that, at present, compounded peptides claiming to be semaglutide or tirzepatide cannot be trusted. There's uncertainty about their composition, and they may pose risks or prove ineffective, po...
Semaglutide as a supplement to lifestyle obesity interventions in multiple countries. When Semaglutide has become commercially unavailable, digital weight-loss services (DWLSs) have prescribed a compounded form of the medication—a practice in which health professionals formulate a replica of the ...